Fracture Risk Spikes With Thiazolidinediones

Rosiglitazone and pioglitazone are both associated with an increased risk of fracture in postmenopausal women with type 2 diabetes, according to a matched case-control study that used data from the Translating Research into Action for Diabetes trial.

After controlling for age, sex, race/ethnicity, body mass index, and health plan, Dori Bilik of the University of Michigan, Ann Arbor, and colleagues, found that both of the thiazolidinediones (TZDs) were associated with a 71% increase in the risk of fracture for women aged 50 and older.

TRIAD enrolled 11,927 patients with diabetes in 2000-2001. All of the patients were at least aged 18 years and in managed care for at least 18 months before the baseline patient survey.

“Our study shows that increased fracture risk is associated with higher TZD dose, but no difference between rosiglitazone and pioglitazone is apparent, suggesting a class effect of TZDs on fracture risk,” said senior author Dr. William Herman of the University of Michigan Ann Arbor, in a press release.

Higher TZD doses were associated with a statistically significant 42% increase in the odds of fractures for women age 50 and older, but not for women under 50 or for men (J. Clin. Endocrinol. Metab. 2010; doi:10.1210/jc2009-2638).

The Centers for Disease Control and Prevention and the National Institute of Diabetes and Digestive and Kidney Diseases funded the study. The authors did not report other conflicts of interest.

Rosiglitazone and pioglitazone are both associated with an increased risk of fracture in postmenopausal women with type 2 diabetes, according to a matched case-control study that used data from the Translating Research into Action for Diabetes trial.

After controlling for age, sex, race/ethnicity, body mass index, and health plan, Dori Bilik of the University of Michigan, Ann Arbor, and colleagues, found that both of the thiazolidinediones (TZDs) were associated with a 71% increase in the risk of fracture for women aged 50 and older.

TRIAD enrolled 11,927 patients with diabetes in 2000-2001. All of the patients were at least aged 18 years and in managed care for at least 18 months before the baseline patient survey.

“Our study shows that increased fracture risk is associated with higher TZD dose, but no difference between rosiglitazone and pioglitazone is apparent, suggesting a class effect of TZDs on fracture risk,” said senior author Dr. William Herman of the University of Michigan Ann Arbor, in a press release.

Higher TZD doses were associated with a statistically significant 42% increase in the odds of fractures for women age 50 and older, but not for women under 50 or for men (J. Clin. Endocrinol. Metab. 2010; doi:10.1210/jc2009-2638).

The Centers for Disease Control and Prevention and the National Institute of Diabetes and Digestive and Kidney Diseases funded the study. The authors did not report other conflicts of interest.

Rosiglitazone and pioglitazone are both associated with an increased risk of fracture in postmenopausal women with type 2 diabetes, according to a matched case-control study that used data from the Translating Research into Action for Diabetes trial.

After controlling for age, sex, race/ethnicity, body mass index, and health plan, Dori Bilik of the University of Michigan, Ann Arbor, and colleagues, found that both of the thiazolidinediones (TZDs) were associated with a 71% increase in the risk of fracture for women aged 50 and older.

TRIAD enrolled 11,927 patients with diabetes in 2000-2001. All of the patients were at least aged 18 years and in managed care for at least 18 months before the baseline patient survey.

“Our study shows that increased fracture risk is associated with higher TZD dose, but no difference between rosiglitazone and pioglitazone is apparent, suggesting a class effect of TZDs on fracture risk,” said senior author Dr. William Herman of the University of Michigan Ann Arbor, in a press release.

Higher TZD doses were associated with a statistically significant 42% increase in the odds of fractures for women age 50 and older, but not for women under 50 or for men (J. Clin. Endocrinol. Metab. 2010; doi:10.1210/jc2009-2638).

The Centers for Disease Control and Prevention and the National Institute of Diabetes and Digestive and Kidney Diseases funded the study. The authors did not report other conflicts of interest.